S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
NASDAQ:SGMO

Sangamo Therapeutics (SGMO) Stock Price, News & Analysis

$1.11
-0.05 (-4.31%)
(As of 03/1/2024 ET)
Today's Range
$1.06
$1.17
50-Day Range
$0.42
$1.38
52-Week Range
$0.29
$3.00
Volume
1.67 million shs
Average Volume
3.52 million shs
Market Capitalization
$196.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.68

Sangamo Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
321.2% Upside
$4.68 Price Target
Short Interest
Bearish
5.49% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Sangamo Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.82) to ($0.48) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.32 out of 5 stars

Medical Sector

581st out of 951 stocks

Biological Products, Except Diagnostic Industry

97th out of 155 stocks


SGMO stock logo

About Sangamo Therapeutics Stock (NASDAQ:SGMO)

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

SGMO Stock Price History

SGMO Stock News Headlines

Sangamo Therapeutics, Inc. (SGMO)
Sangamo Therapeutics (SGMO) Earnings Dates & Reports
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Where Sangamo Therapeutics Stands With Analysts
What 8 Analyst Ratings Have To Say About Sangamo Therapeutics
What To Know About RBC Capital's Downgrade of Sangamo Therapeutics
Sangamo Therapeutics earnings preview: what Wall Street is expecting
See More Headlines
Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2023
Today
3/03/2024
Next Earnings (Estimated)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGMO
CUSIP
80067710
Employees
478
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$4.68
High Stock Price Target
$10.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+321.2%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-192,280,000.00
Net Margins
-123.88%
Pretax Margin
-126.13%

Debt

Sales & Book Value

Annual Sales
$111.30 million
Book Value
$1.80 per share

Miscellaneous

Free Float
172,027,000
Market Cap
$196.86 million
Optionable
Optionable
Beta
1.43

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Alexander D. Macrae Ch.B (Age 61)
    M.B., MRCP, Ph.D., CEO, President & Director
    Comp: $1.17M
  • Ms. Prathyusha Duraibabu CPA (Age 45)
    M.B.A., Senior VP, CFO & Principal Accounting Officer
    Comp: $628.08k
  • Ms. Amy Pooler Ph.D.
    Head of Research
  • Mr. Gregory Davis Ph.D.
    Head of Technology
  • Ms. Aron Feingold
    Head of Corporate Communications & Investor Relations Officer
  • Mr. Scott B. Willoughby (Age 49)
    Senior VP, General Counsel & Corporate Secretary
  • Dr. Nathalie Dubois-Stringfellow Ph.D. (Age 62)
    Senior VP & Chief Development Officer
  • Dr. Lisa Rojkjaer M.D. (Age 58)
    Chief Medical Officer
  • Phillip Ramsey
    Head of Technical Operations
  • Ms. Stephanie J. Seiler CLP
    Head of Business Development & Alliance Management














SGMO Stock Analysis - Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SGMO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGMO, but not buy additional shares or sell existing shares.
View SGMO analyst ratings
or view top-rated stocks.

What is Sangamo Therapeutics' stock price target for 2024?

7 Wall Street analysts have issued 12 month price targets for Sangamo Therapeutics' shares. Their SGMO share price targets range from $1.00 to $10.00. On average, they expect the company's stock price to reach $4.68 in the next year. This suggests a possible upside of 321.2% from the stock's current price.
View analysts price targets for SGMO
or view top-rated stocks among Wall Street analysts.

How have SGMO shares performed in 2024?

Sangamo Therapeutics' stock was trading at $0.5433 at the beginning of 2024. Since then, SGMO stock has increased by 104.3% and is now trading at $1.11.
View the best growth stocks for 2024 here
.

When is Sangamo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our SGMO earnings forecast
.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) released its earnings results on Wednesday, February, 22nd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04. The biopharmaceutical company earned $27.23 million during the quarter, compared to analysts' expectations of $26.86 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 61.40% and a negative net margin of 123.88%. Sangamo Therapeutics's quarterly revenue was down 2.7% compared to the same quarter last year. During the same period last year, the business posted ($0.26) earnings per share.

What ETFs hold Sangamo Therapeutics' stock?

ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and Morningstar US Small Growth (MSGR).Global X Genomics & Biotechnology ETF (GNOM).

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.10%), Wasatch Advisors LP (6.99%), Northern Trust Corp (0.71%), GSA Capital Partners LLP (0.61%), Assenagon Asset Management S.A. (0.58%) and Nuveen Asset Management LLC (0.42%). Insiders that own company stock include Biogen Inc, Gary Loeb and John Markels.
View institutional ownership trends
.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SGMO) was last updated on 3/3/2024 by MarketBeat.com Staff